Home Stock

Stock Research: Tandem Diabetes

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Tandem Diabetes

NMQ:TNDM US8753722037
32
  • Value
    62
  • Growth
    33
  • Safety
    Safety
    39
  • Combined
    43
  • Sentiment
    31
  • 360° View
    360° View
    32
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Tandem Diabetes Care, Inc. is a global company specializing in insulin delivery and diabetes technology. It operates in the medical device industry, with products including the Tandem Mobi system and the t:slim X2 insulin pump. The company operates globally. In the last fiscal year, the company had a market cap of $1,022 million, profits of $490 million, revenue of $940 million, and 2650 employees.

more

ANALYSIS: With an Obermatt 360° View of 32 (better than 32% compared with alternatives), overall professional sentiment and financial characteristics for the stock Tandem Diabetes are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Tandem Diabetes. Only the consolidated Value Rank has an attractive rank of 62, which means that the share price of Tandem Diabetes is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 62% of alternative stocks in the same industry. All other consolidated ranks are below average. The consolidated Growth Rank has a low rank of 33, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The consolidated Safety Rank has a riskier rank of 39, meaning the company has a riskier financing structure than 61% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, professionals are more pessimistic about the stock than for 69% of alternative investment opportunities, reflected in the consolidated Sentiment Rank of 31. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Price vs. Earnings (P/E)
Country USA
Industry Health Care Equipment
Size Medium
Website tandemdiabetes.com
Index
NASDAQ
D.J. US Medical Equipment
Tandem Diabetes stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
62 37 45 17
Growth
33 63 15 79
Safety
Safety
39 15 39 44
Sentiment
31 60 49 12
360° View
360° View
32 36 9 24
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
19 47 21 18
Opinions Change
64 49 50 18
Pro Holdings
n/a 48 49 46
Market Pulse
28 67 67 51
Sentiment
31 60 49 12
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
62 37 45 17
Growth
33 63 15 79
Safety Safety
39 15 39 44
Combined
43 31 17 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
70 46 56 36
Price vs. Earnings (P/E)
97 46 46 15
Price vs. Book (P/B)
7 23 39 27
Dividend Yield
1 1 1 1
Value
62 37 45 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
20 55 45 57
Profit Growth
4 15 40 100
Capital Growth
68 69 17 19
Stock Returns
75 85 31 93
Growth
33 63 15 79
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
11 37 30 39
Refinancing
92 60 61 33
Liquidity
17 18 43 57
Safety Safety
39 15 39 44

Similar Stocks

Discover high‑ranked alternatives to Tandem Diabetes and broaden your portfolio horizons.

Zimmer

NYQ:ZBH
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

ResMed

NYQ:RMD
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Humana

NYQ:HUM
Country: USA
Industry: Health Care Managed
Size: Large
Full Stock Analysis

Innoviva

NSQ:INVA
Country: USA
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

The only strength is good value. All other factors (growth, safety, and sentiment) are below average. This stock is highly sensitive to a crisis and is not advisable. Avoid unless you have solid, independent reasons to believe a significant turnaround is imminent.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews